Clinical Trial: A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy

U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06968585) titled 'A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy' on April 26.

Brief Summary: Evaluation of the efficacy of A166 versus trastuzumab emtansine (T-DM1) in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with trastuzumab and taxane therapy

Study Start Date: July 18, 2023

Study Type: INTERVENTIONAL

Condition: HER2-positive Breast Cancer

Intervention: DRUG: A166

intravenous(IV) infusion (Q3W)

DRUG: T-DM1

intravenous(IV) infusion (Q3W)

Recruitment Status: ACTIVE...